These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 27056735)

  • 1. Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort.
    Ayub A; Parkash O; Naeem B; Murtaza D; Khan AH; Jafri W; Hamid S
    Indian J Gastroenterol; 2016 Mar; 35(2):117-22. PubMed ID: 27056735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
    Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
    J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).
    Bundhun PK; Teeluck AR; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):3. PubMed ID: 28056809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
    Vaduganathan M; Cannon CP; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Bhatt DL;
    Am J Med; 2016 Sep; 129(9):1002-5. PubMed ID: 27143321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
    Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
    Yasu T; Ikee R; Miyasaka Y; Chubachi H; Saito S
    Yakugaku Zasshi; 2010 Dec; 130(12):1743-50. PubMed ID: 21139402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of co-administration of clopidogrel and proton pump inhibitors.
    Shrestha K; Hughes JD; Lee YP; Parsons R
    Qual Prim Care; 2011; 19(1):35-42. PubMed ID: 21703110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
    Vaduganathan M; Bhatt DL; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Cannon CP;
    J Am Coll Cardiol; 2016 Apr; 67(14):1661-71. PubMed ID: 27012778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
    Häuptle R; Weilenmann D; Schneider T; Haile SR; Ammann P; Knellwolf C; Borovicka J
    Wien Med Wochenschr; 2012 Feb; 162(3-4):67-73. PubMed ID: 22476595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.
    Morneau KM; Reaves AB; Martin JB; Oliphant CS
    J Manag Care Pharm; 2014 Feb; 20(2):187-93. PubMed ID: 24456320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
    Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K;
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.
    Yasuda H; Yamada M; Sawada S; Endo Y; Inoue K; Asano F; Takeyama Y; Yoshiba M
    Intern Med; 2009; 48(19):1725-30. PubMed ID: 19797827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
    Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation.
    Luinstra M; Naunton M; Peterson GM; Bereznicki L
    J Clin Pharm Ther; 2010 Apr; 35(2):213-7. PubMed ID: 20456741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
    Burkard T; Kaiser CA; Brunner-La Rocca H; Osswald S; Pfisterer ME; Jeger RV;
    J Intern Med; 2012 Mar; 271(3):257-63. PubMed ID: 21726302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
    Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?
    Lettino M
    Eur J Intern Med; 2010 Dec; 21(6):484-9. PubMed ID: 21111931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton-pump inhibitors can decrease gastrointestinal bleeding after percutaneous coronary intervention.
    Jiang Z; Wu H; Duan Z; Wang Z; Hu K; Ye F; Zhang Z
    Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):636-41. PubMed ID: 23684576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.